What You Will Learn

A clinical study report (CSR) is an essential building block of a clinical submission. The ICH and FDA provide guidance for the structure and content of CSRs and instances when an abbreviated or synoptic CSR format should be used in place of a full CSR format, depending on the role of the CSR in a submission. Thoughtful selection of the CSR format based on study attributes, along with tailoring the template to include the appropriate data will help create a regulatory-compliant CSR and a successful downstream submission.

Attendees will learn about:

  • Relevant regulatory guidance for CSR format and content
  • How to select a suitable CSR format based on study attributes
  • Examples of templates to facilitate authoring a fit-for-purpose CSR
  • How to tailor a CSR to fit submission needs and regulatory requirements

Who Will Benefit from Attending?

  • Clinical Operations/Development Professionals
  • Regulatory Affairs Professionals
  • Medical Writers
Our Experts
Dr. Michelle Reed
Senior Medical Writer
Nicole Rudolph
Manager, Regulatory and Medical Writing
Laura Alionte
Senior Principal Medical Writer

Register Now

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

webinar

March 26th, 2024

Type II Drug Master Files for Early-Stage, Small Molecule, Drug Development: Regulatory Management, Quality Considerations, and eCTD Submission

webinar

January 18th, 2024

Blueprint for Success for Effective and Efficient Clinical Protocols

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

news

November 8th, 2024

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Reflections on the Recent Donanemab Approval

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

perspectives

July 16th, 2024

Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives

June 21st, 2024

Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry